Becton Dickinson and Co Stock (US0758871091): Valuation Metrics Under the Microscope

Becton Dickinson and Co shares continue to trade solidly in the large-cap medical technology space, drawing attention for their current valuation metrics, dividend profile, and balance sheet trends on the NYSE.

Responsible: ad hoc news Markets & Valuation Desk. Reviewed prior to publication on June 11, 2026 at 4:41 PM ET. Details in the imprint.

Becton Dickinson and Co, a global provider of medical devices and diagnostic products, remains a closely watched large-cap name on the New York Stock Exchange under the ticker BDX, with its valuation profile again in focus for US retail investors. The stock recently traded in the high $140s in US trading, corresponding to roughly 148.38 USD in one quoted snapshot, implying only a modest single-digit percentage move over the past trading sessions rather than a sharp swing. With no fresh quarterly earnings or analyst rating changes reported today, the key lens for looking at Becton Dickinson and Co is its current valuation, including its price-to-earnings ratio, dividend yield, and balance sheet indicators compared with the broader medical technology sector. Market participants are also paying attention to how the company’s earnings growth outlook lines up with its current multiple and whether the shares trade at a premium or discount to peers in the S&P 500 health care equipment group.

How Becton Dickinson and Co is currently valued on the market

Becton Dickinson and Co is widely followed as a major medical technology and life sciences supplier, operating in three primary segments: BD Medical, BD Life Sciences, and BD Interventional. The company develops and sells a wide range of products, including syringes, infusion systems, blood collection products, diagnostic instruments, and surgical devices, serving hospitals, laboratories, and clinicians worldwide. As a result, its financial profile reflects both recurring consumables revenue and capital equipment sales, which together shape the multiples investors are willing to pay for the stock.[Company] Public data show that Becton Dickinson and Co generates annual revenue in the tens of billions of US dollars, with fiscal 2024 sales in the neighborhood of more than $20 billion according to company filings and recent reports, placing it among the larger players in the global medical technology industry. This scale, combined with a diversified product set, tends to support relatively stable cash flows, which is one reason the stock often trades at a valuation multiple somewhat above the broader market.

On a trailing earnings basis, Becton Dickinson and Co has typically commanded a price-to-earnings (P/E) ratio in the low to mid-20s in recent months, depending on the specific earnings definition used (GAAP versus adjusted) and the exact share price at any given time. When compared with the S&P 500’s historical average P/E in the mid-teens to high-teens range, this suggests that investors assign a moderate premium to Becton Dickinson and Co’s shares, reflecting its entrenched position in the medical device supply chain and the relatively defensive nature of health care spending. Sector comparisons indicate that major medical-technology peers also often trade around or above 20 times earnings, so Becton Dickinson and Co’s valuation is broadly in line with other large-cap health care equipment names rather than being an outlier. For valuation watchers, the question is less whether the stock is dramatically overvalued or undervalued and more how its earnings growth trajectory and margin profile justify that sector-level multiple.

Looking at forward valuation, analysts commonly publish estimates based on next-twelve-month earnings, which smooth near-term volatility and factor in known product launches and cost efforts. Market data suggest that Becton Dickinson and Co’s forward P/E ratio sits somewhat below the trailing figure, indicating that consensus expects earnings growth over the coming year. When a stock’s forward P/E is lower than its trailing P/E, it typically signals anticipated earnings expansion that could make the valuation less demanding if the price remains unchanged. For Becton Dickinson and Co, this relationship aligns with the company’s ongoing focus on higher-margin product categories and efficiency initiatives across manufacturing and supply chain. While the precise growth rates differ across sources, the broader picture points to mid-single-digit to high-single-digit revenue growth translating into somewhat higher earnings growth as margin initiatives take hold.

Beyond the simple P/E ratio, investors often evaluate Becton Dickinson and Co using the price-to-sales (P/S) and enterprise-value-to-EBITDA (EV/EBITDA) ratios to get a fuller picture of valuation. A P/S ratio in the low single digits, combined with a double-digit operating margin profile, can indicate that the market is not paying an excessive premium for each dollar of revenue, especially when that revenue is relatively stable and diversified. EV/EBITDA, which adjusts for debt levels and cash, is particularly useful for companies with significant leverage, as it approximates how the entire business is valued relative to its core earnings before interest, taxes, depreciation, and amortization. For Becton Dickinson and Co, EV/EBITDA multiples reported in financial databases are consistent with a mature, high-quality medical device company: not at the speculative high-growth extreme, but clearly valued above cyclical industrial names due to the resilience of health care demand. In practice, this means that valuation-sensitive investors compare Becton Dickinson and Co not just with the S&P 500, but with specific health care equipment and life sciences peers when judging whether the stock is attractively priced.

Dividend characteristics form another pillar of Becton Dickinson and Co’s valuation profile, particularly for income-oriented shareholders. The company has a long history of paying dividends and is often cited among firms that have consistently returned cash to shareholders through regular quarterly distributions. At recent price levels in the high $140s, the dividend yield translates to a modest low-single-digit percentage, reflecting both the steady payout and the relatively elevated share price for a large-cap medical technology leader. While the yield is not high by utility or telecom standards, it compares reasonably with other health care equipment peers, many of which also maintain yields in the 1 to 2 percent range. The payout ratio, calculated as dividends per share divided by earnings per share, has generally stayed at a level compatible with ongoing reinvestment in research and development and bolt-on acquisitions, which helps support Becton Dickinson and Co’s growth over time. Income-focused investors often view such a balanced capital allocation approach as supportive of long-term value, even if the near-term yield appears modest.

Becton Dickinson and Co’s balance sheet is a further valuation consideration, particularly after periods of acquisition-driven expansion that can increase leverage. Historical data show that the company has carried a meaningful but manageable debt load, often represented by a net-debt-to-EBITDA ratio in the low- to mid-single-digit range depending on the period examined. Ratings agencies typically evaluate this leverage against the stability of cash flows, and Becton Dickinson and Co has generally maintained investment-grade credit ratings, indicating confidence in its ability to service its obligations. For valuation purposes, a solid credit profile and access to funding at reasonable rates can justify higher enterprise-value multiples, as the risk of financial distress is perceived to be lower. At the same time, investors track progress on deleveraging after major acquisitions as a signal that management is balancing growth ambitions with balance-sheet discipline. When leverage trends downward over time, some market participants may be more willing to accept the existing valuation or even assign a modest premium to reflect reduced financial risk.

Return on capital metrics, such as return on equity (ROE) and return on invested capital (ROIC), also factor into how investors judge Becton Dickinson and Co’s valuation. Companies that generate ROE and ROIC meaningfully above their cost of capital can justify higher valuation multiples, since each dollar reinvested in the business creates additional value for shareholders. Data reported across financial platforms indicate that Becton Dickinson and Co has historically posted double-digit ROE, though this figure can be influenced by leverage and any one-time items in earnings. ROIC, which attempts to strip out capital structure effects, is particularly important for medical technology firms that invest heavily in R&D, manufacturing capacity, and acquisitions. For Becton Dickinson and Co, sustained ROIC in the high single digits or better tends to be viewed positively, especially when combined with stable margins and recurring consumables revenue. In a valuation context, these profitability indicators support the notion that the company can continue to earn attractive returns on incremental investment, which is one reason the market has been willing to pay sector-normal multiples for the stock.

From a relative valuation perspective, Becton Dickinson and Co is often compared with other large-cap health care equipment names listed on major US exchanges, including S&P 500 peers. These peer comparisons typically examine P/E, EV/EBITDA, revenue growth, margin profiles, and dividend policies side by side. For example, some competitors may offer higher near-term revenue growth due to exposure to fast-expanding niches such as robotic surgery or advanced imaging, but they may trade at correspondingly higher multiples than Becton Dickinson and Co. Others with slower growth or more cyclical exposure may be cheaper on headline metrics but lack the same level of recurring consumables revenue. In that context, Becton Dickinson and Co frequently appears as a balanced option, positioned between high-growth, high-multiple names and slower-growth, low-multiple value plays. Whether investors see its current valuation as appealing often depends on their risk tolerance and view of long-term demand for core medical supplies and diagnostic products.

For now, the valuation discussion around Becton Dickinson and Co is shaped less by dramatic day-to-day price swings and more by its fundamentals, including earnings growth prospects, balance sheet strength, and the resilience of health care demand. Investors watching the stock may therefore focus on upcoming catalysts such as future quarterly earnings reports, regulatory clearances for new products, and any capital allocation updates that could influence estimates and, in turn, the multiples the market is willing to assign. Against this backdrop, Becton Dickinson and Co remains an actively followed name in the NYSE-listed health care equipment universe, with its valuation metrics closely tracked as part of broader portfolio allocation decisions in the sector.

Becton Dickinson and Co at a glance

• Name: Becton, Dickinson and Co
• Industry: Medical technology and health care equipment
• Headquarters: Franklin Lakes, New Jersey, United States
• Core markets: Hospitals, laboratories, and health care providers worldwide
• Revenue drivers: Medical devices, diagnostic instruments, and related consumables
• Listing: New York Stock Exchange, ticker BDX
• Trading currency: US dollars (USD)

This article was created with a.i. assistance and editorially reviewed. Not investment advice, not a buy or sell recommendation. Trading in securities carries risks up to the total loss of capital.